{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T00:39:41Z","timestamp":1792629581929,"version":"4.5.0"},"reference-count":79,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.ucl.2013.01.005","type":"journal-article","created":{"date-parts":[[2013,2,19]],"date-time":"2013-02-19T11:18:37Z","timestamp":1361272717000},"page":"197-210","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects"],"prefix":"10.1016","volume":"40","author":[{"given":"Joshua G.","family":"Griffin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff","family":"Holzbeierlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib1","first-page":"2186","article-title":"A\u00a0single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib2","first-page":"2314","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib3","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.eururo.2008.04.051","article-title":"EAU\u00a0guidelines on non-muscle-invasive urothelial carcinoma of the bladder","volume":"54","author":"Babjuk","year":"2008","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib4","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/0090-4295(86)90372-9","article-title":"Absorption of anticancer drugs through bladder epithelium","volume":"27","author":"Mishina","year":"1986","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2013.01.005_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-3-642-81994-0_2","article-title":"Intravesical chemotherapy of superficial bladder cancer","volume":"85","author":"Lum","year":"1983","journal-title":"Recent Results Cancer Res"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib6","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0094-0143(21)00419-5","article-title":"Complications of intravesical chemotherapy","volume":"19","author":"Thrasher","year":"1992","journal-title":"Urol Clin North Am"},{"issue":"7","key":"10.1016\/j.ucl.2013.01.005_bib7","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1021\/tx3002065","article-title":"A\u00a0new mechanism of\u00a0action for the anticancer drug mitomycin C: mechanism-based inhibition of thioredoxin reductase","volume":"25","author":"Paz","year":"2012","journal-title":"Chem Res Toxicol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1053\/ctrv.2000.0202","article-title":"Mitomycin C: a clinical update","volume":"27","author":"Bradner","year":"2001","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1556\/MOnkol.52.2008.1.11","article-title":"Az extravazacio jelentosege az onkologiai apolasban","volume":"52","author":"Zatkone Puskas","year":"2008","journal-title":"Magy Onkol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib10","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.seminoncol.2005.11.007","article-title":"Extravasation of chemotherapeutic agents: prevention and treatment","volume":"33","author":"Goolsby","year":"2006","journal-title":"Semin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib11","first-page":"347","article-title":"Systemic therapy emergencies","volume":"27","author":"Albanell","year":"2000","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/0272-0590(89)90306-0","article-title":"Cardiac, renal, and pulmonary toxicity of several mitomycin derivatives in rats","volume":"13","author":"Bregman","year":"1989","journal-title":"Fundam Appl Toxicol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib13","first-page":"36","article-title":"Pneumopathie interstitielle et mitomycine C. A propos d\u2019un cas avec etude du lavage broncho-alveolaire","volume":"51","author":"Coetmeur","year":"1995","journal-title":"Rev Pneumol Clin"},{"issue":"9","key":"10.1016\/j.ucl.2013.01.005_bib14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1200\/JCO.1986.4.9.1405","article-title":"Vascular toxicity associated with antineoplastic agents","volume":"4","author":"Doll","year":"1986","journal-title":"J\u00a0Clin Oncol"},{"issue":"7","key":"10.1016\/j.ucl.2013.01.005_bib15","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0210-4806(09)74237-8","article-title":"Mitomicina C endovesical y fibrosis pulmonar","volume":"33","author":"Janeiro Pais","year":"2009","journal-title":"Actas Urol Esp"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/BF03007863","article-title":"Pulmonary toxicity of antineoplastic agents: anaesthetic and postoperative implications","volume":"30","author":"Klein","year":"1983","journal-title":"Can Anaesth Soc J"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib17","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1177\/106002809202600404","article-title":"Mitomycin-induced pulmonary toxicity: case report and review of the literature","volume":"26","author":"Linette","year":"1992","journal-title":"Ann Pharmacother"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.005_bib18","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/1097-0142(1971)28:5<1314::AID-CNCR2820280534>3.0.CO;2-D","article-title":"Renal toxicity in man treated with mitomycin C","volume":"28","author":"Liu","year":"1971","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib19","first-page":"152","article-title":"La nephrotoxicite de la mitomycine C. Trois nouvelles observations et revue de la litterature","volume":"3","author":"Simon","year":"1982","journal-title":"Nephrologie"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/jcp.36.1.24","article-title":"Haemolytic-uraemic syndrome complicating long-term mitomycin C and 5-fluorouracil therapy for gastric carcinoma","volume":"36","author":"Crocker","year":"1983","journal-title":"J\u00a0Clin Pathol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib21","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00000421-198406000-00016","article-title":"Renal toxicity of mitomycin-C","volume":"7","author":"Ravikumar","year":"1984","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib22","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/1097-0142(19850101)55:1<47::AID-CNCR2820550108>3.0.CO;2-#","article-title":"Renal complications of mitomycin C therapy with special reference to the total dose","volume":"55","author":"Valavaara","year":"1985","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0277-5379(87)90014-9","article-title":"Mitomycin C-induced renal toxicity, a dose-dependent side effect?","volume":"23","author":"Verwey","year":"1987","journal-title":"Eur J Cancer Clin Oncol"},{"issue":"16","key":"10.1016\/j.ucl.2013.01.005_bib24","first-page":"4347","article-title":"Bladder wall penetration of intravesical mitomycin C in dogs","volume":"51","author":"Wientjes","year":"1991","journal-title":"Cancer Res"},{"issue":"14","key":"10.1016\/j.ucl.2013.01.005_bib25","first-page":"3314","article-title":"Penetration of mitomycin C in human bladder","volume":"53","author":"Wientjes","year":"1993","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib26","first-page":"30","article-title":"Studies of mitomycin C absorption after intravesical treatment of superficial bladder tumors","volume":"132","author":"Wajsman","year":"1984","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib27","first-page":"277","article-title":"Phase I study of high-dose mitomycin with autologous bone marrow support","volume":"66","author":"Sarna","year":"1982","journal-title":"Cancer Treat Rep"},{"issue":"7","key":"10.1016\/j.ucl.2013.01.005_bib28","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S0006-2952(98)00307-4","article-title":"A\u00a0critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin","volume":"57","author":"Gewirtz","year":"1999","journal-title":"Biochem Pharmacol"},{"issue":"2 Pt 1","key":"10.1016\/j.ucl.2013.01.005_bib29","first-page":"374","article-title":"Pharmacokinetics\u00a0of intravesical doxorubicin in superficial bladder cancer patients","volume":"152","author":"Chai","year":"1994","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.005_bib30","doi-asserted-by":"crossref","first-page":"788","DOI":"10.2165\/00003495-199345050-00011","article-title":"Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy","volume":"45","author":"Plosker","year":"1993","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib31","first-page":"153","article-title":"A\u00a0randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta\/T1 transitional cell carcinoma of the bladder","volume":"171","author":"Koga","year":"2004","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib32","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000030242","article-title":"Absorption of epirubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer","volume":"60","author":"Tsushima","year":"1998","journal-title":"Urol Int"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.005_bib33","article-title":"Intravesical Bacillus Calmette-Guerin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.ucl.2013.01.005_bib34","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1046\/j.1464-410x.2000.00911.x","article-title":"The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer","volume":"86","author":"Yamamoto","year":"2000","journal-title":"BJU Int"},{"key":"10.1016\/j.ucl.2013.01.005_bib35","article-title":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guerin","author":"Dinney","year":"2012","journal-title":"Urol Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF00296255","article-title":"Effects of N-trifluoroacetyladriamycin-14-valerate (AD-32) on human bladder tumor cell lines","volume":"19","author":"Niell","year":"1987","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib37","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","article-title":"Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder","volume":"49","author":"Greenberg","year":"1997","journal-title":"Urology"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib38","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0090-4295(00)00654-3","article-title":"Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer","volume":"56","author":"Patterson","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.ucl.2013.01.005_bib39","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0140-6736(61)90304-X","article-title":"Thiotepa in the treatment of tumours of the bladder","volume":"2","author":"Jones","year":"1961","journal-title":"Lancet"},{"key":"10.1016\/j.ucl.2013.01.005_bib40","first-page":"72","article-title":"Absorption studies on intraluminal thio-tepa for topical cytostatic treatment of low-stage bladder tumors","volume":"106","author":"Lunglmayr","year":"1971","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.005_bib41","first-page":"889","article-title":"Thiotepa-induced myelosuppression: review of 670 bladder instillations","volume":"130","author":"Soloway","year":"1983","journal-title":"J\u00a0Urol"},{"issue":"Suppl\u00a05","key":"10.1016\/j.ucl.2013.01.005_bib42","doi-asserted-by":"crossref","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib43","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study","volume":"56","author":"B\u00f6hle","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.005_bib44","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.urology.2009.05.094","article-title":"Systemic absorption and pharmacokinetics of single-dose intravesical gemcitabine after transurethral resection of the bladder in non-muscle-invasive bladder cancer","volume":"74","author":"Maffezzini","year":"2009","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib45","first-page":"2500","article-title":"Distribution of DT-diaphorase and reduced nicotinamide adenine dinucleotide phosphate: cytochrome p450 oxidoreductase in bladder tissues and tumors","volume":"166","author":"Li","year":"2001","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib46","first-page":"116","article-title":"Safety and side effects of immediate instillation of apaziquone following transurethral resection in patients with nonmuscle invasive bladder cancer","volume":"180","author":"Hendricksen","year":"2008","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib47","first-page":"1233","article-title":"The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up","volume":"155","author":"Tolley","year":"1996","journal-title":"J\u00a0Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib48","first-page":"1120","article-title":"Effectiveness of a single immediate mitomycin C instillation in patients with low risk superficial bladder cancer: short and long-term followup","volume":"161","author":"Solsona","year":"1999","journal-title":"J\u00a0Urol"},{"issue":"3 Pt 2","key":"10.1016\/j.ucl.2013.01.005_bib49","first-page":"934","volume":"153","author":"Bouffioux","year":"1995","journal-title":"J\u00a0Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/j.1464-410X.2006.05965.x","article-title":"Immediate administration of intravesical mitomycin C after tumour resection for superficial bladder cancer","volume":"97","author":"Mostafid","year":"2006","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib51","first-page":"749","volume":"149","author":"Oosterlinck","year":"1993","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.ucl.2013.01.005_bib52","first-page":"68","article-title":"Intravesical epirubicin versus doxorubicin for superficial bladder tumors (stages pTa and pT1): a randomized prospective study","volume":"158","author":"Ali-el-Dein","year":"1997","journal-title":"J\u00a0Urol"},{"issue":"9","key":"10.1016\/j.ucl.2013.01.005_bib53","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1002\/cncr.10496","article-title":"Randomized study of single early instillation of (2\u2033R)-4\u2032-O-tetrahydropyranyl-doxorubicin for a single superficial bladder carcinoma","volume":"94","author":"Okamura","year":"2002","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib54","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/j.1464-410X.1985.tb07031.x","article-title":"The effect of intravesical thiotepa on the recurrence rate of newly diagnosed superficial bladder cancer. An MRC Study. MRC Working Party on Urological Cancer","volume":"57","year":"1985","journal-title":"Br J Urol"},{"issue":"11","key":"10.1016\/j.ucl.2013.01.005_bib55","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1111\/j.1464-410X.2008.07898.x","article-title":"Increasing patient comfort by optimized postoperative administration of intravesical mitomycin C","volume":"102","author":"Stoehr","year":"2008","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib56","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1046\/j.1464-410x.1999.00951.x","article-title":"Perivesical fat necrosis after adjuvant intravesical chemotherapy","volume":"83","author":"Doherty","year":"1999","journal-title":"BJU Int"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib57","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.purol.2010.02.008","article-title":"Necrose vesicale dans les suites d\u2019une instillation postoperatoire precoce (Ipop) de mitomycine C","volume":"21","author":"Branchereau","year":"2011","journal-title":"Prog Urol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib58","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1159\/000241684","article-title":"Perivesical inflammation and necrosis due to mitomycin C instillation after transurethral resection of bladder tumor: we must be vigilant!","volume":"83","author":"Fazlioglu","year":"2009","journal-title":"Urol Int"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1046\/j.1464-410x.2000.00539.x","article-title":"Perivesical inflammation after early mitomycin C instillation","volume":"85","author":"Cliff","year":"2000","journal-title":"BJU Int"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0302-2838(03)00151-9","article-title":"Unusual complication after immediate postoperative intravesical mitomycin C instillation","volume":"43","author":"Nieuwenhuijzen","year":"2003","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib61","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1097\/01.ju.0000181811.61199.35","article-title":"The actual\u00a0incidence of bladder perforation following transurethral bladder surgery","volume":"17","author":"Balbay","year":"2005","journal-title":"The Journal of Urology"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib62","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.eururo.2004.05.003","article-title":"One immediate postoperative instillation of chemotherapy in low risk Ta, T1 bladder cancer patients. Is it always safe?","volume":"46","author":"Oddens","year":"2004","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.005_bib63","first-page":"4269","article-title":"Vesicoenteric, vesicovaginal, vesicocutaneous fistula -an unusual complication with intravesical mitomycin","volume":"15","author":"Dangle","year":"2008","journal-title":"Can J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib64","first-page":"3317","article-title":"Risk of post-operative intravesical mitomycin C instillation following transurethral bladder tumor resection","volume":"13","author":"Shapiro","year":"2006","journal-title":"Can J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib65","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1365-2133.1990.tb08268.x","article-title":"Dermatitis due to intravesical mitomycin C: a delayed-type hypersensitivity reaction?","volume":"122","author":"Colver","year":"1990","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.ucl.2013.01.005_bib66","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0536.1991.tb01699.x","article-title":"Systemic allergic contact dermatitis from intravesical instillation of the antitumor antibiotic mitomycin C","volume":"24","author":"de Groot","year":"1991","journal-title":"Contact Dermatitis"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib67","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1034\/j.1600-0536.2000.042002074.x","article-title":"Type III and type IV hypersensitivity reactions due to mitomycin C","volume":"42","author":"Kunkeler","year":"2000","journal-title":"Contact Dermatitis"},{"issue":"7","key":"10.1016\/j.ucl.2013.01.005_bib68","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1346-8138.2009.00668.x","article-title":"Drug eruption due to intravesical instillations of both epirubicin and mitomycin C","volume":"36","author":"Okumura","year":"2009","journal-title":"J\u00a0Dermatol"},{"issue":"8","key":"10.1016\/j.ucl.2013.01.005_bib69","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1586\/14737140.6.8.1273","article-title":"Intravesical\u00a0mitomycin C for superficial transitional cell carcinoma","volume":"6","author":"Bolenz","year":"2006","journal-title":"Expert Rev Anticancer Ther"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib70","first-page":"1306","article-title":"Necrosis of the glans penis: a rare complication of intravesical therapy with mitomycin c","volume":"164","author":"Neulander","year":"2000","journal-title":"J\u00a0Urol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib71","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jaad.2005.07.041","article-title":"Cutaneous complications of intravesical treatments for bladder cancer: granulomatous inflammation of the penis following BCG therapy and penile gangrene following mitomycin therapy","volume":"55","author":"Kureshi","year":"2006","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.ucl.2013.01.005_bib72","first-page":"459","article-title":"Bone marrow suppression after intravesical mitomycin C treatment","volume":"136","author":"Zein","year":"1986","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib73","first-page":"2004","article-title":"Complications of intravesical therapy for urothelial cancer of the bladder","volume":"175","author":"Koya","year":"2006","journal-title":"J\u00a0Urol"},{"issue":"8471","key":"10.1016\/j.ucl.2013.01.005_bib74","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0140-6736(86)91928-8","article-title":"Benign ulcers after bladder instillation of mitomycin C","volume":"1","author":"Richards","year":"1986","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib75","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1464-410X.1990.tb14959.x","article-title":"Reduced bladder capacity in patients receiving intravesical chemoprophylaxis with mitomycin C","volume":"66","author":"Eijsten","year":"1990","journal-title":"Br J Urol"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib76","first-page":"19","article-title":"Calcification de la paroi vesicale apres instillation de la mitomycine\u00a0C. A propos d\u2019une observation","volume":"63","author":"Pouya","year":"1995","journal-title":"Acta Urol Belg"},{"issue":"4","key":"10.1016\/j.ucl.2013.01.005_bib77","first-page":"1071","article-title":"Bladder wall calcification after intravesical mitomycin C treatment of superficial bladder cancer","volume":"142","author":"Drago","year":"1989","journal-title":"J\u00a0Urol"},{"issue":"5","key":"10.1016\/j.ucl.2013.01.005_bib78","first-page":"1239","article-title":"Bladder wall calcification after topical mitomycin C","volume":"138","author":"Alter","year":"1987","journal-title":"J\u00a0Urol"},{"issue":"6","key":"10.1016\/j.ucl.2013.01.005_bib79","first-page":"2166","article-title":"Mitomycin C and epirubicin: functional bladder damage in rats after repeat intravesical instillations","volume":"173","author":"Michielsen","year":"2005","journal-title":"J\u00a0Urol"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014313000062?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014313000062?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:24:08Z","timestamp":1758806648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014313000062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0094014313000062"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2013.01.005","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Side Effects of Perioperative Intravesical Treatment and Treatment Strategies for These Side Effects","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2013.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}